Suven Life Sciences Initiates Phase I Clinical Trials in Europe of SUVN-502 for Alzheimer’s Disease
News Jun 24, 2008
Suven Life Sciences Ltd announced at Bio-2008, San Diego that they commenced Phase I clinical trials of SUVN-502, a potent, safe, highly selective, brain penetrant and orally active antagonist at a nonperipheral CNS receptor site 5-HT6, intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson, Schizophrenia.
Stimulation of 5-HT6 receptors in the brain has been shown to increase the release of acetylcholine and glutamate levels and has shown activity in several animal models with cognitive-enhancing properties of memory impairment.
The study is being conducted at Basel, Switzerland under a Clinical Trial Application (CTA) approved by SwissMedic, the regulatory authority of Switzerland.
The Phase I study being conducted using single and multiple oral doses with the objective of assessing safety and bioavailability of SUVN-502 in 67 healthy human beings. The single ascending dose (SAD) studies are expected to be complete by Sept-2008 and multiple ascending dose (MAD) studies are to be conducted during Oct-Dec 2008.
"SUVN-502 is an exciting molecule which fared very well in preclinical studies and the first NCE of Suven to enter the clinic from a pipeline of six NCEs. The CNS market and especially the cognition is amongst the largest, about $20 billion potential market opportunity globally and this novel target presents an excellent opportunity," says Venkat Jasti, CEO of Suven Life Sciences Ltd.
"Pre-clinical studies have demonstrated SUVN-502 to be highly potent, safe and orally available with good bioavailability across species tested. The molecule also exhibited excellent selectivity over other targets. We believe that SUVN-502 has great potential to become a novel treatment for disorders affecting memory and cognition in Alzheimer’s and other dementia” says Dr. Ramakrishna Nirogi, Vice President, Discovery Research, Suven Life Sciences.
A new study by investigators from Brigham and Women’s Hospital examined whether pregnancy-related changes may influence how effectively five common AEDs prevent seizures and found that antiepileptic drug clearance significantly changes by the first trimester for the most commonly used medication and by the second trimester for two others.READ MORE
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019